N Engl J Med 2026: Landmark N Engl J Med study demonstrating CD19 CAR-T cell therapy as a novel curative approach for refractory autoimmune hemolytic anemia, achieving durable remission in patients who failed multiple lines of immunosuppression.

Donor-derived CD7 CAR-T Cells for Pediatric and Adult Relapsed/Refractory T-ALL/LBL

Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

J Hematol Oncol 2025: Phase 1 single-center trial demonstrating that BCMA/GPRC5D bispecific CAR-T achieves high response rates in multiple myeloma patients with extramedullary disease—a historically refractory population.

Lancet Haematol 2025: Phase 2 single-center trial confirming GPRC5D as an effective second target for anti-BCMA-progressed multiple myeloma, achieving meaningful responses in heavily pretreated patients.